ReviewWorld journal of urology2025
Post-HIFU surveillance of localized prostate cancer: role of PSMA-PET imaging versus the standard PSA-mpMRI protocol.
Review in World journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrating Multiparametric MRI and PSMA PET Imaging in Prostate Cancer: Toward a Unified Diagnostic and Risk-Stratification Paradigm.Medicina (Kaunas, Lithuania) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIntermediate-risk prostate cancer (PCa) is a heterogeneous subgroup for which the optimal treatment strategy remains a subject of debate. Of all the emerging options, high-intensity focused ultrasound (HIFU) therapy aims to treat the tumor while preserving healthy prostate structures. However, the post-treatment surveillance protocol remains poorly defined, particularly due to the limitations of PSA testing and conventional imaging. This narrative review evaluates the contribution of PSMA-PET metabolic imaging in post-HIFU follow-up compared to standard techniques (PSA, multiparametric MRI).
methodsA narrative review of the literature was conducted in the Medline, PubMed, and Cochrane (2008-2025) databases. Studies evaluating post-HIFU follow-up by PSA, mpMRI, and/or PSMA-PET were included. Data were analyzed descriptively and critically by two independent reviewers.
resultsEight studies were included out of the 1245 identified articles. Although mpMRI is currently standard, its sensitivity and specificity in the treated area is limited due to post-HIFU anatomical changes. The recently developed PI-FAB score improves the standardization of interpretation but remains operator-dependent. On the other hand, PSMA-PET offers excellent specificity (100%) and satisfactory sensitivity in detecting occult recurrences, even when PSA levels are low and including after mpMRI and systematic biopsies have failed.
conclusionPSMA-PET is a molecular imaging modality that appears promising for post-HIFU surveillance of favorable intermediate-risk prostate cancer. As a complement to PSA testing and multiparametric MRI, it can refine the detection and localization of recurrences and, in doing so, influence the selection and sequencing of salvage therapies in routine practice. Prospective studies are still needed to establish its impact on treatment decision-making and long-term oncologic outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.